Inotuzumab ozogamicin for MRD-positive B-ALL

Inotuzumab ozogamicin for MRD-positive B-ALL

Phase II study of inotuzumab ozogamicin in MRD+ B-ALLПодробнее

Phase II study of inotuzumab ozogamicin in MRD+ B-ALL

Blinatumomab vs inotuzumab ozogamicin for ALLПодробнее

Blinatumomab vs inotuzumab ozogamicin for ALL

When to Use Inotuzumab Ozogamicin for Adult ALLПодробнее

When to Use Inotuzumab Ozogamicin for Adult ALL

Inotuzumab ozogamicin for treating pediatric R/R ALLПодробнее

Inotuzumab ozogamicin for treating pediatric R/R ALL

Inotuzumab ozogamicin & venetoclax in the treatment of B-ALL: findings from a Phase I trialПодробнее

Inotuzumab ozogamicin & venetoclax in the treatment of B-ALL: findings from a Phase I trial

What is the role of inotuzumab ozogamicin in ALLПодробнее

What is the role of inotuzumab ozogamicin in ALL

Relapsed/Refractory ALL: Inotuzumab OzogamicinПодробнее

Relapsed/Refractory ALL: Inotuzumab Ozogamicin

Phase II trial of inotuzumab ozogamicin to treat MRD+ B-ALLПодробнее

Phase II trial of inotuzumab ozogamicin to treat MRD+ B-ALL

The importance of blinatumomab and inotuzumab ozogamicin in treating ALLПодробнее

The importance of blinatumomab and inotuzumab ozogamicin in treating ALL

Inotuzumab ozogamicin and blinatumomab prior to and after alloHSCT in R/R Ph+ ALLПодробнее

Inotuzumab ozogamicin and blinatumomab prior to and after alloHSCT in R/R Ph+ ALL

Dr. Brammer on Data With Inotuzumab Ozogamicin in ALLПодробнее

Dr. Brammer on Data With Inotuzumab Ozogamicin in ALL

Choosing between inotuzumab ozogamicin and blinatumomab in patients with R/R ALLПодробнее

Choosing between inotuzumab ozogamicin and blinatumomab in patients with R/R ALL

Emerging novel approaches for ALL: inotuzumab ozogamicinПодробнее

Emerging novel approaches for ALL: inotuzumab ozogamicin

Inotuzumab ozogamicin for the treatment of elderly acute lymphoblastic leukemiaПодробнее

Inotuzumab ozogamicin for the treatment of elderly acute lymphoblastic leukemia

Hyper-CVAD with blinatumomab and inotuzumab ozogamicin for patients with newly diagnosed Ph- B-ALLПодробнее

Hyper-CVAD with blinatumomab and inotuzumab ozogamicin for patients with newly diagnosed Ph- B-ALL

What’s next for inotuzumab ozogamicin in ALL?Подробнее

What’s next for inotuzumab ozogamicin in ALL?

Dose-adjusted EPOCH plus inotuzumab ozogamicin for B-ALLПодробнее

Dose-adjusted EPOCH plus inotuzumab ozogamicin for B-ALL

MRD-Positive ALL: Personal Approaches to TreatmentПодробнее

MRD-Positive ALL: Personal Approaches to Treatment

Novel ALL treatment strategies: inotuzumab ozogamicinПодробнее

Novel ALL treatment strategies: inotuzumab ozogamicin